Promedior Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, has announced that retrospective…
Articles by Charles Moore
FibroGen Inc. will present the full data set from a clinical study of patients with Idiopathic Pulmonary Fibrosis (IPF),…
Photo Caption: “The Process is the product” – Pluristem’s 3D expansion technology allows for the production of different PLX…
Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are not popular topics of media coverage and popular conversation in the…
Irving, Texas based Reata Pharmaceuticals, Inc. has enrolled the first patient in a Phase 2 dose ranging study…
Researchers in a major study based at Brigham and Women’s Hospital (BWH) in Boston, Massachusetts, have linked development…
Genomics development and commercialization specialist firm Synthetic Genomics Inc. (SGI) of La Jolla, CA, and Silver Spring, Maryland-based…
The American College of Chest Physicians (CHEST) has announced updates to its Pulmonary Arterial Hypertension guidelines in the online…
A small pilot study by a team of French researchers has established the long-term benefits of upfront triple combination therapy among…
Results released Monday, May 5th from Canada’s Pulmonary Hypertension Association (PHA) Patient and Caregiver Survey revealed that those…